Retina

Biomarkers and fine-tuned staging are key to progress in improving retinal care, according to Fanka Gilevska, MD, PhD

NPI-001 is Nacuity’s investigational therapy for the treatment of patients with retinitis pigmentosa (RP).

Additionally, the company also received Clinical Trial Authorisation (CTA) approval from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA).

As of October 1, 2025, the Centers for Medicare & Medicaid Services (CMS) has assigned a permanent J-code (J3403) to revakinagene taroretcel-lwey.

The trial results show promising for the evaluated gene therapy for the treatments of LCA, showing significant vision improvements in pediatric patients.

Patient response focused on perceived vision-related quality of life outcomes, investigators said

Dr Miere presented the ACTOR study, illuminating vascular remodeling in patients with neovascular AMD, and the HERMES study, investigating perfusion changes in central retinal vein occlusion

Miere discusses retinal studies on AMD and vein occlusion, highlighting imaging advancements and the future of machine learning in treatment predictions.

María Berrocal, MD, spoke about the Vit-Buckle Society (VBS), which has become a regular feature at the European Society of Retina Specialists annual meeting

Explore the Fight Retinal Blindness! Project, a global registry enhancing VEGF inhibitor treatment outcomes with comprehensive data and insights for better patient care.

Explore how digital image management and AI transform ophthalmology, enhancing diagnostics and personalizing patient care in retina practices.

Subramanian discusses how subtle retinal and optic nerve findings can point to underlying neurologic disease.

Prof Romano stressed the importance of matching procedure to patient, not just mastering technical vitrectomy skills

In honor of looking back at 50 years, we look forward at a world where the toughest eye diseases could be cured in the blink of an eye.

Research on methotrexate's role in PVR retinal detachment surgery shows promising visual improvements, potentially transforming treatment strategies in ophthalmology.

EyeArt uses artificial intelligence for autonomous detection of vision-threatening diabetic retinopathy

EYLUXVI (ALT-L9) is an aflibercept (Eylea) biosimilar from Alteogen, co-developed by its subsidiary, Alteogen Biologics.

Today, over 150 practitioners from 20 countries in Australia, Asia and Europe enter their patient data into the Fight Retinal Blindness! Registry

The submission was based on the safety and efficacy data from the phase 3 (RHODOS) and phase 4 (LEROS) studies.